Those who invested in Veracyte (NASDAQ:VCYT) a year ago are up 68% [Yahoo! Finance]
Veracyte, Inc. (VCYT)
Last veracyte, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.veracyte.com/investor-relations
Company Research
Source: Yahoo! Finance
For example, the Veracyte, Inc. NASDAQ:VCYT ) share price is up 68% in the last 1 year, clearly besting the market return of around 30% (not including dividends). If it can keep that out-performance up over the long term, investors will do very well! The longer term returns have not been as good, with the stock price only 8.2% higher than it was three years ago. Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns. Check out our latest analysis for Veracyte Veracyte wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually desire strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size. Over the last twelve months, Veracyte's revenue grew by 24%. T
Show less
Read more
Impact Snapshot
Event Time:
VCYT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VCYT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCYT alerts
High impacting Veracyte, Inc. news events
Weekly update
A roundup of the hottest topics
VCYT
News
- Is Your Portfolio Missing These 5 High-Growth Healthcare Stocks? [Yahoo! Finance]Yahoo! Finance
- 3 Medical Instruments Industry Stocks to Buy on the GenAI Wave [Yahoo! Finance]Yahoo! Finance
- Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines [Yahoo! Finance]Yahoo! Finance
- Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer GuidelinesBusiness Wire
- Veracyte, Inc. (NASDAQ: VCYT) had its "neutral" rating re-affirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $37.00 price target on the stock, down previously from $38.00.MarketBeat
VCYT
Earnings
- 11/6/24 - Beat
VCYT
Sec Filings
- 12/17/24 - Form 4
- 12/13/24 - Form 144
- 12/6/24 - Form 4
- VCYT's page on the SEC website